SKSertaç Ketenci

Sertaç Ketenci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sertaç Ketenci has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cervical spine instability in axial spondyloarthritis: prevalence, patterns, and predictive factors in a high-risk cohort

    by S Ketenci, A Kababıyık, H Oğuzman, M Pekdiker

    Axial spondyloarthritis (axSpA) is a group of chronic, inflammatory rheumatic diseases that primarily affect the spine and sacroiliac joints, typically beginning in the third decade of life. This d...

  • Open Access

    Atlantoaxial instability in psoriatic arthritis: Frequency and correlated factors from a single-center cohort

    by Mete Pekdiker, Huban Yilmaz, Sertaç Ketenci, Mete Kara

    Objectives: There is very limited data regarding atlantoaxial instability (AAI) in patients with psoriatic arthritis (axPsA). In this study, we aimed to contribute to the existing literature on this topic. Methods: Adult patients were included in this single-center study who were classified as PsA by the ‘CASPAR’ criteria and evaluated as having axial involvement according to the ‘Calin’ criteria. Those with inflammatory or non-inflammatory diseases that could affect the spine were excluded. Electronic patient files were reviewed retrospectively. Lateral neutral/full extension/full flexion and open-mouth anteroposterior cervical radiographs were evaluated by three rheumatologists blinded to the patients. Patients were compared in two groups as AAI-positive and AAI-negative. Results: A total of 100 patients with a mean age of 48.8 years and a mean PsA duration of 7.4 years, 57% of whom were female, were included in the study. A total of 20 AAI lesions were detected in 18% patients; subaxial subluxation was detected in eight, anterior atlantoaxial subluxation (AAS) in seven, posterior AAS in three, lateral AAS in one, and vertical subluxation in one case. In the group with AAI, the presence of psoriasis (Ps) (p = 0.037), scalp psoriasis (p < 0.001), and the use of targeted therapy for Ps and PsA (p < 0.001, p < 0.001) were significantly higher than in the AAI-negative group. Conclusion: Given that Ps and PsA patients on targeted therapy may reflect cases with higher disease activity and inadequate response to conventional treatments, it may be appropriate to consider closer monitoring for AAI in these patients. Key Points • Atlantoaxial instability is present in approximately one-fifth of patients with axial psoriatic arthritis .• The most common instability lesion is subaxial subluxation, accounting for 40% of all lesions .• The presence of psoriasis, scalp psoriasis, and the use of targeted therapies for psoriatic arthritis or psoriasis are significantly more frequent in the group with atlantoaxial instability. These factors may be useful for cervical spine monitoring in patients with axial psoriatic arthritis . • The use of targeted therapies for psoriatic arthritis or psoriasis may indirectly indicate an association between high disease activity and atlantoaxial instability .

  • Open Access

    Effectiveness of ultrasonography-guided pericapsular nerve group block in patients with adhesive capsulitis resistant to conservative treatment: A prospective observational study

    by Bora Uzuner, Selma İşLer, Sertaç Ketenci, Dilek Durmuş

    : This prospective observational study aimed to evaluate the effectiveness of ultrasonography-guided pericapsular nerve group block (PENG-b) in shoulder pain, function, and kinesiophobia in patients with adhesive capsulitis (AC) resistant to conservative treatment. Sixty-one patients diagnosed with resistant AC were included in this study. Thirty-one patients received PENG-b followed by mobilization (Group 1), while 30 received only mobilization therapy (Group 2). All patients underwent mobilization therapy thrice a week for 6 weeks, targeting ≥80% shoulder range of motion (ROM). Pain was assessed using the Visual Analog Scale, function using the Disabilities of the Arm, Shoulder, and Hand questionnaire and Modified Constant-Murley Score, ROM via goniometry, and kinesiophobia using the Tampa Scale. Group 1 reached the targeted ROM in 10.3 ± 1.6 sessions (range 6–12), whereas all patients in Group 2 required 18 sessions ( P < .001). Both groups showed significant posttreatment improvements in Visual Analog Scale, ROM, Modified Constant-Murley Score, Disabilities of the Arm, Shoulder and Hand, and kinesiophobia scores ( P < .001). However, Group 1 demonstrated significantly superior outcomes across all measures compared to Group 2 ( P < .001). Pain relief was also observed within 24 hours after injection in Group 1. PENG-b provided rapid pain relief and enhanced the effectiveness of subsequent mobilization therapy, resulting in better functional recovery and reduced kinesiophobia within a shorter timeframe. These findings suggest that PENG-b is a safe and effective pre-rehabilitation intervention for patients with AC who are unresponsive to conventional treatments.

  • The frequency of sarcopenia in HIV patients: Effects on functional performance

    by Bora Uzuner, Erdal Hancı, Dilek Durmuş, Sertaç Ketenci, Muharrem Yüksel, Elifsu Beniç, Aydın Deveci

    Aim: The present study aims to determine the prevalence of sarcopenia in Human Immunodeficiency Virus Infection (HIV) patients and to evaluate functional performance.Material and Methods: 67 patients with HIV and 50 healthy control were included in the study. For detection for sarcopenia, the thighs of both lower extremities were measured using the Modified Sonographic Tight Adjustment Ratio (STAR) method, which was obtained by adding the bilateral rectus femoris and vastus intermedius muscle thicknesses measured by ultrasound. Hand muscle strength (HMS) was measured with a dynamometer. Knee Muscle strength (KMS) was measured isokinetic muscle testing. Physical performance was determined using timed up-and-go test (TUGT), 5-repetition sit-to-stand test (5RSTS), and 6-min walk test (6MWT). Results:According to the STAR values calculated based on body mass index, sarcopenia was present in 10 (17.5%) of 57 male patients. Sarcopenia was not detected in female patients. There was no significant difference with respect to demographic characteristics among the two groups. HMS, KMS, TUGT, 5RSTS and 6MWT values were significantly different in two groups (p

  • Open Access

    Cervical Spine Involvement in Rheumatoid Arthritis: Does Joint Erosion Severity Correlate with Instability?

    by Mete Pekdiker, Sertaç Ketenci

    Objectives: Although numerous risk factors associated with cervical spine involvement (CSI) have been reported in the literature, the relationship between the severity of peripheral joint erosions and CSI has not yet been investigated. In this study, we aimed to investigate this relationship. Materials and Methods: Adult rheumatoid arthritis (RA) patients with a disease duration of more than 5 years were enrolled from 2 tertiary rheumatology clinics. Medical records were retrospectively reviewed. Neutral, open-mouth anteroposterior, full flexion, and full extension cervical spine radiographs, along with hand radiographs, were assessed independently by 2 blinded rheumatologists. “RA-type joint involvement (RJI)” was defined as presence of any erosion or joint space narrowing (JSN) as per the Modified Sharp Score (MSS). “Severe joint involvement (SJI)” was defined as presence of any erosion with a score of ≥ 3 points or JSN with a score of ≥ 4 points as per the MSS. Results: We enrolled 238 patients, 84.5% of whom were female, and the mean age was 58.1 Å} 12.1 years. The frequency of CSI was 19.7% (n = 47), including anterior atlantoaxial subluxation (AAS) (42.3%), posterior AAS (7%), lateral AAS (22.5%), vertical subluxation (11.5%), and subaxial subluxation (12.7%). The CSI-positive group had longer lag time to diagnosis (P = .028), longer disease duration (P = .002), higher rates of RJI (P = .047), SJI (P < .001), and peripheral joint ankylosis (PJA) (P < .001) than CSI-negative group. In multivariate analysis, only PJA remained an independent predictor of CSI (P < .001). In addition, there was no significant difference in the frequency of interstitial lung disease and chronic knee/elbow arthritis between the CSI-positive and CSI-negative groups. Conclusion: To our knowledge, this is the first study to identify PJA as an independent risk factor for CSI. Therefore, RA patients having PJA should be carefully screened for CSI.

  • Rapid Improvement of Fatigue and Sleep in Active Rheumatoid Arthritis with Anti-TNF Therapy: A Retrospective Observational Study

    by Bora Uzuner, Sertaç Ketenci, Ender Salbaş, Ayhan Bilgici

    Objective: Patients with rheumatoid arthritis (RA) suffer from high burdens of fatigue and poor sleep quality which persist even when joint inflammation is controlled. We aimed to retrospectively evaluate the 3-month impact of initiating anti-TNF therapy initiation on fatigue sleep quality and functional status in patients with active RA. Methods: We conducted a 3-month single-center retrospective cohort study reviewing the records of 39 patients with active RA (Disease Activity Score 28 [DAS28] > 5.1) despite stable csDMARDs. A matched group of 36 healthy controls was used for baseline comparisons. Patients had initiated adalimumab, etanercept, or infliximab. Assessments had been performed at baseline and 3 months using the DAS28 (disease activity), Health Assessment Questionnaire (HAQ), Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), Pittsburgh Sleep Quality Index (PSQI), and Beck Depression Inventory (BDI). 31 patients had completed the 3-month follow-up and had complete data for analysis. Results: At 3 months, patients showed significant clinical improvement. Mean DAS28 decreased from 5.5 ± 1.2 to 3.3 ± 1.6 (p < 0.001) and 39% (12/31) achieved remission. Significant improvements were seen in patient-reported outcomes. The mean MFSI-SF total fatigue score decreased from 27.6 to 10.4 (p < 0.001) and the mean global PSQI score improved from 9.5 to 7.0 (p < 0.001). Functional status (HAQ) and depressive symptoms (BDI) also improved significantly (both p < 0.001). At baseline, fatigue strongly correlated with poor sleep (r=0.626), depression (r=0.674), and HAQ (r=0.656). Improvement in fatigue correlated moderately with improvement in depression (Δ-BDI r=0.571). Conclusion: Anti-TNF therapy provides rapid and significant improvements not only in clinical disease activity but also in the key patient-reported burdens of fatigue, sleep quality, and depression within three months of initiation. Keywords: rheumatoid arthritis, anti-TNF therapy, fatigue, sleep quality,

  • Open Access

    Comparative efficacy of rituximab in biologic/targeted synthetic DMARD-naive versus exposed rheumatoid arthritis patients: a retrospective cohort study

    by Sertaç Ketenci, Mete Kara

    Objective: To compare the efficacy and safety of rituximab in patients with rheumatoid arthritis (RA) who were either biologic/targeted synthetic DMARD (bDMARD/tsDMARD)-naive or previously exposed. Methods: In this retrospective cohort study, 120 RA patients treated with rituximab between June 2020 and December 2023 were included. Patients were categorized as bDMARD/tsDMARD-naive (n=66) or -exposed (n=54). Clinical efficacy was assessed by change in Disease Activitity Score 28 (DAS28)-CRP and the proportion achieving low disease activity (LDA; DAS28-CRP <3.2) after treatment. Safety outcomes included infusion-related reactions (IRRs), infections, and hypogammaglobulinemia. Results: The naive group showed significantly greater improvement in disease activity (ΔDAS28-CRP: 2.5 vs. 1.9, p=0.001) and higher LDA achievement (62.1% vs. 46.2%, p=0.030) compared to the exposed group. Rates of IRRs (16.6% vs. 18.5%, p=0.820), infections (1.5% vs. 1.9%, p=0.880), and hypogammaglobulinemia were comparable between groups. Most IRRs were mild (grade 1–2); only one serious IRR occurred, with no cases requiring prolonged hospitalization. One patient in the exposed group experienced hepatitis B reactivation, managed effectively with antiviral therapy. Primary and secondary inefficacy were the most common reasons for rituximab discontinuation, with no significant differences between groups. Conclusion: Rituximab demonstrated superior efficacy in bDMARD/tsDMARD-naive RA patients, while maintaining a comparable safety profile to that in previously exposed patients. These findings support the potential benefit of using Rituximab earlier in the treatment sequence for selected RA patients.

  • Tracking Cartilage Turnover: Urinary CTX-II as a Biomarker for Early Rheumatoid Arthritis Progression and Anti-TNF Therapy Response

    by Bora Uzuner, Ayhan Bilgici, Sertaç Ketenci, Ender Salbaş, Abdulkerim Bedir

    Introduction: This study aimed to evaluate urinary C-telopeptide of type II collagen (CTX-II) as a biomarker of cartilage turnover, disease activity, and anti-TNF therapy response in rheumatoid arthritis (RA), with a focus on early disease. Methods: In a prospective cohort study (June–October 2010), 39 RA patients initiating anti-TNF therapy (adalimumab, etanercept, or infliximab) and 36 age- and sex-matched healthy controls were enrolled. Baseline and 3-month assessments included urinary CTX-II (corrected for creatinine), Disease Activity Score in 28 joints (DAS28), Health Assessment Questionnaire (HAQ), and van der Heijde modified Total Sharp Score (mTSS). Correlations between CTX-II and disease activity or radiographic damage were analyzed using Spearman’s rank correlation. Changes in CTX-II were assessed with the Wilcoxon signed-rank test, and subgroup analyses compared early (<3 years) versus established RA. Results: At baseline, RA patients had significantly higher urinary CTX-II levels than controls (447.8 ± 359.3 vs. 233.8 ± 122.4 ng/mmol, p<0.005). CTX-II correlated positively with DAS28 (ρ=0.609, p<0.001), HAQ (ρ=0.493, p=0.001), and joint counts, and was twofold higher in RF-positive patients (557.0 ± 395.0 vs. 252.8 ± 159.6 ng/mmol, p=0.018). After 3 months, early RA patients (n=11) showed a significant 45% reduction in CTX-II (p=0.016), while established RA patients (n=20) showed no change (p=0.421). Patients in remission (DAS28 <2.6, n=12) had CTX-II levels comparable to controls (p=0.005). High baseline CTX-II (≥479 ng/mmol, n=8) predicted a 46% reduction post-therapy (p=0.017). Conclusion: Urinary CTX-II is a dynamic biomarker of cartilage turnover and anti-TNF response, particularly in early RA. Its association with RF positivity and remission suggests a role in personalized RA management. Larger studies are needed to validate standardized cut-offs for clinical use.

  • Open Access

    Abnormal Ulnar Variance: A New Perspective in Rheumatoid Arthritis-Related Joint Damage

    by Sertaç Ketenci, Mete Pekdiker, Bora Uzuner, Dilek Durmuş

    Background/Aims: Rheumatoid arthritis (RA) is characterized by significant inflammation and joint damage. This study aims to investigate the frequency of abnormal ulnar variance (AUV) in RA patients and its associated factors. Materials and Methods: A total of 108 established RA patients meeting the 2010 ACR/EULAR RA criteria were included. After exclusions, the study proceeded with 98 patients. Demographic, laboratory, and clinical data were recorded. X-rays of the wrists were taken in accordance with the literature, with the forearm in a neutral rotation, the elbow flexed at 90°, the shoulder abducted at 90°, and ulnar variance was assessed with Hulten's method. A displacement of 1 mm or more of the ulna relative to the radius was defined as AUV. Results: The average age was 58.11 ± 12.05 years, with 82% being female. The mean disease duration was 175.16 ± 100.5 months, and the average diagnostic delay was 16.4 ± 11.18 months. Abnormal ulnar variance was present in 47.9% of patients. In patients with AUV, the average UV for the right hand was +2.24 mm, while the average for the left hand was +2.40 mm. When considering all RA cases, the average UV was +1.06 mm for the right hand and +1.09 mm for the left hand. In the multivariate analysis, RA-type joint involvement (RJI) and severe joint involvement (SJI) were identified as independent predictors of AUV. Conclusion: This study suggests that AUV may be an important finding in established RA. Future larger-scale and prospective studies are needed to elucidate the significance of AUV in RA cases.

  • Open Access

    Evaluating leflunomide and methotrexate combination vs. monotherapy in rheumatoid and psoriatic arthritis

    by Mete Kara, Gülay Alp, Mete Pekdi̇kEr, Sertaç Ketenci̇, Annamaria Porreca, Haluk Ci̇nAkli̇

    Background/aim: Methotrexate (MTX) and leflunomide (LEF) are conventional synthetic disease-modifying antirheumatic drugs (DMARDs) commonly used for treating rheumatoid arthritis (RA) and psoriatic arthritis (PsA), either as monotherapies or in combination. This study aimed to compare the adverse effects (AEs) and efficacy of combined use of MTX plus LEF with monotherapy in RA and PsA patients. Materials and methods: This study included 528 patients (385 RA and 143 PsA) with at least 6 months of follow-up. Disease activity was assessed using DAS-28 CRP and DAPSA, and treatment-related AEs were classified based on specific MedDRA categories. Results: The cumulative incidence of AEs in patients with RA treated with MTX, LEF, and MTX plus LEF was 23.8%, 28.2%, and 19.2%, respectively; in PsA patients, 18.1%, 30%, and 23.3%, respectively. None of the groups were superior to each other in terms of general AEs between monotherapy and in combination. LEF monotherapy in RA was associated with more neurological AEs and hypertension. Compared to monotherapy, MTX plus LEF demonstrated greater reductions in disease activity, a more substantial decrease in glucocorticoid doses, and lower utilization of biological/targeted DMARDs (b/tsDMARDs) in both RA and PsA. In univariate analysis, MTX dosage, initial DAS28 CRP, and b/tsDMARD initiation were predictors of low disease activity (LDA) in RA. In multivariate analysis, MTX dosage (95% CI 1.02–1.59, OR = 1.27, p = 0.031) and initial DAS28-CRP (95% CI 2.14–10.90, OR = 4.38, p < 0.001) were found to be independently associated with LDA in RA. In PsA, the factors associated with LDA were initial DAPSA and disease duration in univariate analysis. Only disease duration was found to be an independent predictor in multivariate analysis (95% CI, 1.02–1.38, OR = 1.17 p = 0.039). Conclusion: Adding LEF to MTX or vice versa may serve as a valuable, safe, and effective alternative in situations where b/tsDMARD therapy is challenging.